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Abstract
Anticholinergics are widely used for the treatment of COPD, and to a lesser extent for asthma.
Primarily used as bronchodilators, they reverse the action of vagally derived acetylcholine on
airway smooth muscle contraction. Recent novel studies suggest that the effects of anticholinergics
likely extend far beyond inducing bronchodilation, as the novel anticholinergic drug tiotropium
bromide can effectively inhibit accelerated decline of lung function in COPD patients. Vagal tone is
increased in airway inflammation associated with asthma and COPD; this results from exaggerated
acetylcholine release and enhanced expression of downstream signaling components in airway
smooth muscle. Vagally derived acetylcholine also regulates mucus production in the airways. A
number of recent research papers also indicate that acetylcholine, acting through muscarinic
receptors, may in part regulate pathological changes associated with airway remodeling. Muscarinic
receptor signalling regulates airway smooth muscle thickening and differentiation, both in vitro and
in vivo. Furthermore, acetylcholine and its synthesizing enzyme, choline acetyl transferase (ChAT),
are ubiquitously expressed throughout the airways. Most notably epithelial cells and inflammatory
cells generate acetylcholine, and express functional muscarinic receptors. Interestingly, recent
work indicates the expression and function of muscarinic receptors on neutrophils is increased in
COPD. Considering the potential broad role for endogenous acetylcholine in airway biology, this
review summarizes established and novel aspects of muscarinic receptor signaling in relation to the
pathophysiology and treatment of asthma and COPD.
Introduction
Acetylcholine is the primary parasympathetic neurotrans-
mitter in the airways, and is traditionally associated with
inducing airway smooth muscle contraction and mucus
secretion. Parasympathetic activity is increased in airway
inflammation, which is the basis for the use of anticholin-
ergic therapy in asthma and chronic obstructive pulmo-
nary disease (COPD) [1]. Anticholinergics constitute a
particularly important bronchodilator therapy in COPD,
as vagal tone appears to be the only reversible component
of airflow limitation in this condition [1]. Recent evidence
indicates that acetylcholine production in the airways is
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not restricted to the parasympathetic nervous system: ace-
tylcholine is also released from non-neuronal origins such
as the bronchial epithelium and inflammatory cells [2].
Furthermore, accumulating evidence suggests acetylcho-
line (either neuronal or non-neuronal) may play an essen-
tial regulatory role in the mechanisms that drive the
structural changes in the airways, called airway remode-
ling, that are associated with chronic airway inflammation
[3,4]. These recent findings indicate that acetylcholine,
acting on muscarinic receptors, may contribute to the
pathophysiology and pathogenesis of asthma and COPD
to a much larger extent than is currently appreciated. This
concept is underscored by findings that the recently intro-
duced long-acting anticholinergic agent, tiotropium bro-
mide [5], markedly inhibits accelerated lung function
decline in COPD patients [6]. This article will review the
established and novel muscarinic receptor signaling
mechanisms in airway physiology, and discuss their
involvement in the pathophysiology of asthma and
COPD. Though nicotinic cholinergic receptors are present
throughout the airways (see [7] for review), their function
will not be discussed in view of the muscarinic receptor
specificity of the current clinically used anticholinergics.
Muscarinic receptor regulation of airway 
smooth muscle tone
Airway smooth muscle expresses abundant muscarinic M2
and M3 receptors, roughly in a 4:1 ratio [8]. Despite its
lower expression levels, the Gq coupled muscarinic M3
receptor is the primary subtype responsible for bronchial
and tracheal smooth muscle contraction; this is evident
from the functional affinities of a variety of subtype selec-
tive antagonists in airway tissues from diverse species,
including humans [8-11] (Table 1). In addition, mus-
carinic M3 receptor -, but not M2 receptor-knockout mice
lack both methacholine and vagally induced bronchocon-
striction in vivo [12]. Nonetheless, some pharmacological
studies have suggested a small role for Gi – coupled M2
receptors in mediating airway smooth muscle contraction
in the peripheral airways [13,14]. Muscarinic receptor reg-
ulation of airway smooth muscle tone is enhanced in
asthma and COPD by two major mechanisms: first,
increased expression and enhanced function of signaling
molecules essential for muscarinic receptor mediated air-
way smooth muscle contraction; and second, exaggerated
release of neuronal acetylcholine due to neuronal mecha-
nisms associated with inflammation.
Intracellular signaling in airway smooth muscle
Muscarinic receptors induce airway smooth muscle con-
traction through a number of intracellular signaling
mechanisms; most of these are well described and have
been reviewed extensively [4,15,16]. These include a
number of recently identified cascades that are of specific
interest to airway inflammation in asthma and COPD
(Figure 1). Several researchers have postulated that
enhanced Ca2+ signaling underpins the genesis of obstruc-
tive airways diseases that are associated with airway hyper-
reactivity [17,18]. In part, this is based on observations
from animal models, for example airway smooth muscle
cells obtained from hyperresponsive Fisher rats show ele-
vated Ca2+ responses when compared to the less respon-
sive Lewis rats [19]. Several studies have also shown that
isolated airway smooth muscle preparations from asthma
and COPD patients respond with increased maximal force
generation to contractile stimulation in vitro [20-24].
Thus, intrinsic abnormalities that contribute to choliner-
gic hyperreactivity may exist in at least a proportion of
asthmatics and COPD patients.
Although the altered expression of the postjunctional
muscarinic M3 receptor on airway smooth muscle cells is
not a feature of airway hyperreactivity to inhaled metha-
choline, changes in downstream signaling from these
receptors may be a contributing factor [16]. In addition to
activating phospholipase Cβ1 (PLC), which leads to inosi-
tol 1,4,5-trisphosphate (IP3) production necessary for
triggering release of intracellular Ca2+ stores, muscarinic
receptors also regulate signaling pathways involving
CD38, cyclic ADP ribose (cADPR) and ryanodine receptor
channels that can play an important role in airway
smooth muscle Ca2+ homeostasis [25] (Figure 1). The
CD38/cADPR pathway contributes significantly to mus-
carinic receptor mediated changes in lung compliance and
resistance, as evident in CD38 knockout mice [26]. Initial
studies suggest that this pathway may be activated selec-
tively by muscarinic M2 receptors [27], though other stud-
ies suggest that muscarinic M3, rather than M2 receptors
are coupled to cADPR production [28]. Several pro-
inflammatory cytokines, including IL-1β [29], IL-13 [30],
Table 1: Affinity profiles of selective and nonselective muscarinic 
receptor antagonists for muscarinic M2 and M3 receptors.
M2*M 3#
4-DAMP 7.8 9.0 [8, 11]
AQ-RA 741 8.3 7.5–6.6 [135]
Gallamine 6.5 4.3 [8]
DAU 5884 6.6 8.7 [14]
Methoctramine 7.5 6.5 [8]
Pirenzepine 6.2 6.8 [8, 11]
AF-DX 116 7.0 5.6–6.3 [8, 11]
Ipratropium 9.7† 9.7† [5]
Tiotropium 10.7† 11.0† [5]
* Data represent binding affinities (pKi) for cardiac muscarinic M2 
receptors
# Data represent functional affinities (pA2) to methacholine-induced 
contraction of tracheal and bronchial preparations.
† Data represent binding affinities (pKi) to cloned human muscarinic 
receptor subtypes.Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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TNF-α [31] and IFN-γ [32] can increase CD38 expression,
ADP-ribosyl cyclase activity, and Ca2+ responses to cholin-
ergic agonists in airway smooth muscle. TNF-α and IL-1β
also increase Gi and Gq alpha protein expression in airway
smooth muscle, which could account for increased Ca2+
responses and contraction [33,34]. Furthermore, treat-
ment of airway smooth muscle strips with IL-13 or TNF-α
for extended periods, induces hyperresponsiveness to
cholinergic agonists [35,36].
Contraction of airway smooth muscle is regulated by Ca2+
dependent and Ca2+ independent mechanisms. Ca2+ inde-
pendent mechanisms are characterized by augmented
contraction at a fixed Ca2+ concentration; this phenome-
Pathways central in muscarinic receptor mediated airway smooth muscle contraction Figure 1
Pathways central in muscarinic receptor mediated airway smooth muscle contraction. Muscarinic receptor (MR) ago-
nists induce contraction of airway smooth muscle by Ca2+ dependent and Ca2+ independent pathways. Through associated Gq 
alpha subunits, the muscarinic M3 receptor activates phospholipase C (PLC), which releases inositol 1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG) after hydrolytic conversion of phosphatidylinositol-4,5-bisphosphate (PIP2). IP3 induces the release of 
Ca2+ from internal sarcoplasmatic reticulum (SR) stores. Coupling of M3 receptor to CD38 through as yet undefined mecha-
nisms contributes to the production of cyclic ADP ribose (cADPR) and the release of Ca2+ through ryanodine receptor chan-
nels in the SR. Ca2+ release increases free cytosolic Ca2+ and promotes calmodulin-dependent activation of myosin light chain 
kinase (MLCK). MLCK mediated phosphorylation of 20 kDa regulatory myosin light chain (MLC) in the contractile apparatus is 
an obligatory event to induce smooth muscle contraction. MLC phosphorylation level is also controlled by pathways that 
inhibit myosin light chain phosphatase (MLCP) and, thus enhance Ca2+ sensitivity. PLC-derived DAG activates protein kinase C 
(PKC), leading to CPI-17 phosphorylation and downstream MLCP inhibition. Rho-kinase, which is activated by the monomeric 
G protein RhoA, both phosphorylates CPI-17 and inhibits MLCP directly. The expression and function of RhoA, CPI-17 and 
CD38 are increased by pro-inflammatory cytokines in vitro and in animal models of asthma and COPD ex vivo (see text).Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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non is referred to as Ca2+ sensitization [37]. Regulation of
Ca2+ sensitivity by cholinergic agonists is an important
step in airway smooth muscle contraction (Figure 1). The
RhoA/Rho-kinase cascade, a key regulatory pathway of
Ca2+ sensitivity in airway smooth muscle, can be activated
by both muscarinic M2  and muscarinic M3  receptors
[38,39]. RhoA and Rho-kinase augment agonist-induced
contraction primarily by inactivating myosin light chain
phosphatase (MLCP), although direct effects on myosin
light chain phosphorylation and on actin cytoskeletal
dynamics have also been described [40]. MLCP is inhib-
ited by the direct phosphorylation of its regulatory
myosin binding subunit by Rho kinase. MLCP is also
inhibited by binding to the phosphoprotein CPI-17,
which is targeted for phosphorylation by both Rho kinase
and PKC (see [37] for detailed review on the role of Rho-
kinase in airway hyperresponsiveness). The anti-spas-
mogenic effects of Rho-kinase inhibition are distinctly
smaller than their relaxant effects on a pre-established
cholinergic contraction, indicating that the RhoA/Rho-
kinase pathway is particularly important in maintaining a
sustained contraction to cholinergic agonists [41-43].
In experimental models of inflammatory airway disease,
muscarinic receptor-linked signaling pathways that regu-
late Ca2+ sensitivity of airway smooth muscle cells appear
to be enhanced. Both RhoA and CPI-17 expression are
increased in rats exposed to repeated allergen challenge
[44,45]. Furthermore, allergic sensitization by itself, with-
out subsequent allergen exposure, appears to be sufficient
to induce an increase in RhoA expression [46]. Cytokines,
including TNFα, have been identified as contributors to
increased RhoA abundance [47]. In line with these obser-
vations, cholinergic agonist-induced RhoA translocation
to the membrane, RhoA-mediated Ca2+ sensitization, and
contraction are increased in bronchial smooth muscle
from rats and mice exposed to repeated allergen challenge
[45,48,49]. Recent observations indicate that the same is
true for cigarette smoke induced airway hyperresponsive-
ness in rat bronchial smooth muscle [50], which could be
of significant importance to the pathophysiology of
COPD. Effects of lipopolysaccharide (LPS) on cholinergic
reactivity of airway smooth muscle have also been
described [51]; however, it is yet to be established what
mechanisms exactly mediate this change.
Neuronal mechanisms
In addition to postjunctional mechanisms that involve
muscarinic receptor signaling in airway smooth muscle
cells, neuronal mechanisms are important, and they also
appear to be affected in inflammatory airways disease
(Figure 2). Neuronal acetylcholine is synthesized by the
enzyme choline acetyl transferase (ChAT), stored in vesi-
cles, and released upon membrane depolarization. Once
released, the functional effects of acetylcholine are termi-
nated primarily by acetylcholinesterase (AChE) in the syn-
aptic cleft. AChE activity is decreased in tracheal smooth
muscle homogenates from ragweed pollen sensitized
dogs [52]; this represents a mechanism to increase and
prolong the action of acetylcholine on postjunctional tar-
get cells, such as airway smooth muscle cells, in allergic
airways diseases. In addition, mediators of inflammation
can enhance the release of acetylcholine from vagal nerve
endings, an effect mediated through prejunctional facili-
tatory receptors. Examples include tachykinins, prostag-
landins and thromboxane A2  [53]. Furthermore, the
autoinhibitory prejunctional muscarinic M2 receptor, that
limits acetylcholine release under normal conditions (Fig-
ure 2), is dysfunctional in several experimental models of
airways disease including allergen exposure, viral infec-
tion, and ozone exposure [54,55]. M2 autoreceptors have
also been reported to be dysfunctional in some, but not
all asthmatics [56,57]. In addition, asthmatics with active
viral infections show greater bronchodilator responses to
inhaled anticholinergics, suggesting an increased vagal
tone [58]. Nonetheless, in patients with stable COPD the
M2 autoreceptor appears to function normally [59]. Dis-
tinct mechanisms underlie the M2 autoreceptor dysfunc-
tion. In guinea pigs, ozone and allergen-induced M2
dysfunction is mediated by eosinophils that are recruited
to airway nerves, and secrete major basic protein, that acts
as an allosteric muscarinic M2 receptor antagonist [55].
Viral infections, which may play a role in both asthma and
COPD, induce M2 dysfunction through neuraminidases
that cleave portions of the M2 receptor, and through as yet
incompletely characterized mechanisms involving macro-
phages, CD8+ lymphocytes, and possibly IFN-γ [60].
Cholinergic neurotransmission in the parasympathetic
ganglia is regulated by nicotinic receptors in conjunction
with muscarinic M1 receptors, whereas ganglionic release
of acetylcholine from preganglionic nerves is under regu-
lation of M2 autoreceptors [61,62] (Figure 2). Though the
M2 autoreceptor can be dysfunctional in allergic airway
inflammation, as described above, currently no evidence
suggests that ganglionic muscarinic M1 receptor expres-
sion is altered [63]. However, several inflammatory medi-
ators facilitate ganglionic neurotransmission, including
tachykinins, histamine, bradykinin and prostaglandins
[64]. Airway ganglia function to filter the signals from the
rapidly firing preganglionic neurons; therefore faciliation
of ganglionic transmission by inflammatory mediators is
likely of significance in the regulation of airway tone [53].
Most of the afferent nerve fibres in the airways are C-fib-
ers, which are present throughout the airways, from the
larynx down to the lung parenchyma. C-fibers respond to
stimuli such as heat and cold, but can also be activated by
inflammatory mediators, resulting in reflex bronchocon-
striction, mucus production and cough [65]. The localiza-Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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tion of the reflex mechanism can be central and local, and
may contribute considerably to the increased vagal tone in
COPD, and to airway hyperreactivity in asthma and
COPD [65,66]. Several inflammatory mediators, includ-
ing histamine, prostanoids, thromboxane A2, bradykinin,
serotonin and tachykinins are known to stimulate sensory
nerve fibres [67]. Afferent sensory nerve endings project to
the subepithelial layer in healthy airways, but may be
exposed to the airway lumen upon the induction of epi-
thelial damage by mediators such as eosinophil-derived
major basic protein [68]. This is considered an important
Cholinergic receptors involved in neuronal acetylcholine release and function Figure 2
Cholinergic receptors involved in neuronal acetylcholine release and function. Neuronal acetylcholine release is regu-
lated by a network of afferent and efferent airway nerves that interact with their surrounding cells. Afferent C-fibers project to 
the subepithelial region where they can be activated by inflammatory mediators and non-specific stimuli. In asthma, epithelial 
damage can expose sensory nerve endings to the airway lumen, potentiating their activation. Activated C-fibers secrete neuro-
kinins (NK) that exert local effects and facilitate ganglionic neurotransmission (peripheral reflex arc). In addition, the activated 
C-fiber increases the output of the vagal nerve through regulation in the central nervous system (CNS) (central reflex arc). 
Neurotransmission in parasympathetic ganglia of the airway is mediated by acetylcholine through nicotinic (N) and muscarinic 
M1 receptors and can be markedly facilitated by inflammatory mediators (see text). Presynaptic muscarinic M2 autoreceptors 
inhibit acetylcholine release and are dysfunctional in airway inflammation. The postganglionic neurons project primarily to 
mucus producing cells and airway smooth muscle, where neurotransmission is regulated by muscarinic M1, M2 and M3 recep-
tors, as indicated. As in the ganglia, prejunctional acetylcholine release is autoinhibited by muscarinic M2 receptors that are dys-
functional in airway inflammation. Acetylcholine release is augmented further by direct effects of inflammatory mediators on 
facilitatory presynaptic receptors. See the text for further detail.Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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mechanism in the regulation of vagally mediated airway
hyperrresponsiveness.
Muscarinic receptor regulation of mucus 
hypersecretion
The production of airway mucus in the central airways is
under cholinergic control, and plays an important role in
asthma and COPD [69,70]. Airway mucus is a protective
film that serves to prevent inhaled particles from damag-
ing the airway epithelium. It is composed of electrolytes,
water and contains high amounts of mucins [69]. Mucins
are glycoproteins that are responsible for the high viscos-
ity of mucus; the primary mucins found in airway mucus
are of the MUC5AC and MUC5B isoforms. Mucus secret-
ing cells in the central airways include goblet cells, which
are embedded in the epithelium, and submucosal glands
that are in connection to the airway lumen. Acetylcholine
is the dominant neurotransmiter involved in mucus secre-
tion in the central airways [71] (Figure 2). Thus, electrical
field stimulation increases mucus production in bron-
chial preparations, which is sensitive to atropine and tet-
rodotoxin [72]. Airway submucosal glands are likely the
primary source of this vagally regulated mucus produc-
tion. Submucosal glands are innervated, and express func-
tional muscarinic M1 and M3 receptors, roughly in a 1:2
ratio [73,74]. The muscarinic M3 receptor is the predomi-
nant receptor that mediates mucus secretion, whereas
electrolyte and water secretion are probably mediated by
muscarinic M3 receptors in cooperation with M1 receptors
[72,75]. Goblet cells can also produce mucus in response
to muscarinic receptor stimulation, albeit at relatively
high concentrations of agonist [71].
Mucus hypersecretion is a pathological feature seen in
both asthma and COPD that contributes significantly to
airflow limitation by obstructing the airways [76]. The
composition of mucus in asthma and COPD is generally
altered, with higher expression of the low charge isoform
MUC5B, particularly in COPD, and with the expression of
small amounts of the insoluble MUC2; in COPD the ratio
of mucus cells to serous cells in the submucosal glands is
also increased [69]. Since mucus production in the central
airways is, to a large extent, vagally mediated, acute airway
inflammation can regulate mucus hypersecretion by aug-
menting acetylcholine release in the same way as
described in the previous section. In addition, cholinergic
receptor stimulation interacts synergistically with epider-
mal growth factor (EGF) on mucus cell activation in air-
way submucosal glands [77]. Since EGF is thought to
regulate goblet cell hyperplasia and mucus gland hyper-
trophy in asthma and COPD [78,79], this may have addi-
tional implications for the effects of muscarinic receptors
on this pathology. Indeed, muscarinic receptor stimula-
tion transactivates the EGF receptor in conjunctival goblet
cells, which is involved in mucin production by these cells
[80]. In addition, based on observations in experimental
animal models, repeated administration of the mus-
carinic agonists pilocarpine and methacholine can pro-
mote goblet cell hyperplasia and mucus gland
hypertrophy [81]. This raises the real possibility that
excessive release of endogenous acetylcholine could pro-
mote remodeling of mucus secreting cells in asthma and
COPD, but this still needs to be assessed in human sub-
jects.
Muscarinic receptor regulation of airway 
inflammation
Traditionally, acetylcholine is not considered to regulate
airway inflammation. Recruited inflammatory cells dis-
tribute throughout the lung, and are not primarily local-
ized to vagal nerves. Early studies suggested that blood
lymphocytes and peripheral polymorphonuclear leuko-
cytes do not express functional muscarinic receptors [82].
This view is changing, however. Accumulating evidence
demonstrates that acetylcholine and its synthesizing
enzyme choline acetyltransferase (ChAT) are present not
only in airway nerves, but localize to epithelial and
endothelial cells, smooth muscle cells, lymphocytes, mac-
rophages, mast cells, eosinophils and neutrophils as well
[2,62]. Furthermore, rigorous investigation has now
revealed that most inflammatory cells express functional
muscarinic receptors (Table 2). These findings suggest that
acetylcholine can regulate inflammatory processes by
paracrine and/or autocrine mechanisms [83-86]. Notably,
elevated levels of acetylcholine have been noted in skin
biopsies from patients with atopic dermatitis, a condition
often associated with bronchial asthma [87].
Mild asthma and stable COPD show distinct patterns in
the nature of airway inflammation. Stable COPD is char-
acterized by pulmonary infiltration of neutrophils, cyto-
toxic (CD8+) T lymphocytes, monocytes and
macrophages, whereas in mild asthma, Th2 (CD4+) lym-
phocytes and eosinophils show a distinct increase. The
nature and extent of the airway inflammation are, how-
ever, dependent on severity of the disease, as in COPD
and acute severe asthma both neutrophils and CD8+ T
lymphocytes are key contributors to disease pathology
[88].
There is considerable evidence that the non-neuronal
cholinergic system plays a role in lymphocytes, although
its relative importance to airway physiology is not yet
established. Mononuclear leukocytes, consisting mainly
of lymphocytes, express ChAT mRNA and protein, con-
tain ACh and express muscarinic and nicotinic receptors.
The expression profile of muscarinic receptors shows high
individual variability, although all 5 classes (M1-M5) of
muscarinic receptors have been detected [83]. Muscarinic
receptor agonists increase cytosolic Ca2+ both in human T-Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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and B-cell lines in an atropine-sensitive manner, and
increase c-fos mRNA expression in response to the mus-
carinic agonist oxotremorine [89]. The latter effect is sen-
sitive to 4-diphenylacetoxy-N-methylpiperidine (4-
DAMP) methobromide, but not to pirenzepine or AF-DX
116, which is consistent with the involvement of mus-
carinic M3 receptors (Table 1). Furthermore, phytohemag-
glutinin (a T-cell activator) increased ChAT mRNA [90]
and muscarinic M5 receptor expression [91] in stimulated
mononuclear leukocytes. The significance of these obser-
vations is that muscarinic receptors and non-neuronal
acetylcholine could contribute to lymphocyte prolifera-
tion and cytokine release, with obvious implications for
airway inflammation in asthma and COPD. Furthermore,
it is established that muscarinic receptors play an impor-
tant role in regulating cytotoxicity of T lymphocytes [92].
Future studies are needed, however, to characterize the
expression and function of the non-neuronal cholinergic
system in lymphocytes that have infiltrated the lungs and
in T lymphocytes that adopted a specific CD8+ or CD4+
phenotype
A recent study by Profita et al. [93] investigated the expres-
sion of muscarinic M1, M2 and M3 receptors in sputum
cells obtained from healthy controls, smokers, and
patients with COPD. In this study, all three subtypes of
muscarinic receptors were observed in macrophages and
neutrophils of all patient groups. M1  receptors were
expressed in low abundance in eosinophils from COPD
patients, but not from healthy controls. Importantly, the
expression of muscarinic M3 receptors on macrophages is
significantly increased in COPD patients, whereas mus-
carinic M2 receptor expression is decreased. The expres-
sion of muscarinic M1 receptors on macrophages, and the
expression of M1 and M3 receptors on neutrophils tended
to be increased, though this did not reach statistical signif-
icance. Functional studies showed that acetylcholine
induced the release of significant amounts of leukotriene
B4 and activated the p42/p44 MAP kinase pathway in spu-
tum cells from COPD patients [93]. Neutrophil chemo-
tactic activity induced by acetylcholine was also increased
in COPD. These results are entirely consistent with a study
demonstrating that bovine alveolar macrophages release
eosinophil, monocyte and neutrophil chemotactic activi-
ties in response to acetylcholine, with probably a predom-
inant involvement of leukotriene B4  [94]. These
observations clearly reveal that regulated expression of
muscarinic receptor subtypes is a feature of inflammatory
cells that migrate to the airways, though the precise func-
tional impact of dynamic receptor expression on these
cells needs to be elucidated.
In addition to its direct effects on inflammatory cells, ace-
tylcholine may also trigger chemokine and cytokine
release from structural cells. Bronchial epithelial cells
release eosinophil, monocyte and neutrophil chemotactic
Table 2: Muscarinic regulation of (airway) inflammation.
Cell type Presence of muscarinic receptors, ChAT and/or 
acetylcholine
Functional effects of acetylcholine
T lymphocyte Muscarinic receptors (M1-M5 *)
ChAT
Acetylcholine
Increased cytotoxicity
Cytokine production
Proliferation
[2, 83, 92]
B lymphocyte Muscarinic receptors (M1-M5 *)
ChAT
Acetylcholine
Proliferation [2, 83]
Mast cell Muscarinic receptors (M1)
ChAT
Acetylcholine
Inhibition of histamine release [2, 136, 137]
Neutrophil Muscarinic receptors (M1/M2/M3)
ChAT
Chemotaxis
LTB4 production #
[93, 138]
Eosinophil Muscarinic receptors (M1)
ChAT
unknown [93, 138]
Macrophage/monocyte Muscarinic receptors (M1/M2/M3)
ChAT
Acetylcholine
LTB4 production # [2, 83, 93]
Bronchial epithelium Muscarinic receptors (M1/M3)
ChAT
Acetylcholine
Release of monocyte, eosinophil and neutrophil 
chemotactic factors
[95, 96, 98]
Airway smooth muscle Muscarinic receptors (M2/M3)
ChAT
Pro-inflammatory gene expression [2, 8, 99]
* Further characterization is necessary: putative presence of muscarinic M1 – M5 receptors shows high variability and is based on their presence in 
mononuclear leukocytes [83].
# Presence of muscarinic receptors on macrophages and neutrophils suggests their involvement in LTB4 production by sputum cells [93].Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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activity in response to acetylcholine [95,96]. Consistent
with the previously mentioned findings, there appears to
be an important role for leukotriene B4 in these effects.
Acetylcholine is also known to induce the release of GM-
CSF from human bronchial epithelial cells by a mecha-
nism that involves nicotinic receptors [97]. Since the
expression of non-neuronal acetylcholine is relatively
high in bronchial epithelial cells [98], these results could
implicate a role for epithelial acetylcholine in initiating
inflammatory responses.
Muscarinic receptors on airway smooth muscle cells may
play a profound role in regulating airway inflammation: a
recent study demonstrates that the muscarinic receptor
agonist carbachol increases inflammatory gene transcrip-
tion in bovine tracheal smooth muscle strips [99]; quanti-
tative RT-PCR analysis demonstrates that carbachol can
modulate expression of a number of genes, including IL-
8, cyclo-oxygenase (COX) 1 and 2 and urokinase type
plasminogen activator (PLAU); and, carbachol markedly
augments pro-inflammatory gene expression induced by
sinusoidal length oscillation, with synergistic effects on
IL-6, IL-8 and COX 2 and to a lesser extent PLAU and CCL-
2 [99]. Collectively these studies suggest acetylcholine is
an autocrine or paracrine hormone that may be involved
in regulating inflammation at a number of cellular sites in
the airways (Table 2). At this point, evidence is lacking
however to indicate a direct involvement of non-neuronal
acetylcholine in the pathophysiology of asthma and
COPD and future studies are clearly warranted within this
area.
Muscarinic receptor regulation of airway 
remodeling
Chronic inflammatory conditions of the airways are usu-
ally associated with the development of structural changes
of the airways; a phenomenon commonly referred to as
airway remodeling. Airway remodeling is seen in both
asthma and COPD, albeit the nature, localization and
extent of the remodeling are variable (Table 3). Airway
remodeling is progressive, both in asthma and COPD,
and the extent of structural change correlates with disease
severity [100-102]. Based on these considerations, it is
believed that most structural changes, e.g. increased air-
ways smooth muscle mass and mucus gland hypertrophy,
contribute to a progressive increase in disease severity over
time and to the irreversible decline in lung function in
patients with chronic disease. Some structural changes on
the other hand, including matrix deposition in the airway
wall, are not necessarily detrimental, but may actually
protect the diseased airway from airway closure by
increasing airway wall stiffness [103,104]. Clearly a com-
plex relationship exists between airway structure and
function. Indeed, at present there is considerable ongoing
research effort using in vitro, ex vivo, and in vivo systems
to clarify key structural determinants of airway and lung
function in health and disease.
Contractile agonists acting on G-protein coupled recep-
tors are increasingly being recognized as key contributors
to airway remodeling in asthma. Cysteinyl leukotrienes
have received significant attention in this regard: the
capacity for anti-leukotrienes to prevent allergen-induced
airway inflammation, mucus production and occlusion,
goblet cell hyperplasia, and most notably airway fibrosis
and airway smooth muscle thickening have been
described [105-109]. Acetylcholine, on the other hand,
has not generally been considered to be a crucial determi-
nant of structural changes in the airways. However, recent
findings are changing this view. Indeed, there may be a
prominent regulatory role for endogenous acetylcholine
in promoting allergen-induced airway remodeling
[4,110]. In the following sections the potential contribu-
tion of acetylcholine to specific components of airway
remodelling are being discussed.
Mesenchymal cell proliferation
Muscarinic receptor stimulation induces profound prolif-
eration of primary cultured human lung fibroblasts [111].
In addition, though stimulation of muscarinic receptors is
Table 3: Airway remodeling in asthma and COPD. Muscarinic receptors and acetylcholine play significant roles in airway smooth 
muscle remodeling, and possibly in goblet cell hyperplasia and mucus gland hypertrophy. Their involvement in other aspects of airway 
remodeling is less well explored.
Asthma COPD
Airway smooth Hyperplasia [121, 139] Increased ASM mass [140]
muscle (ASM) Hypertrophy [101, 139] Hypercontractility [23]
Hypercontractility [20-22, 24]
Mucus production Goblet cell hyperplasia
Mucus gland hypertrophy
[141] Goblet cell hyperplasia
Mucus gland hypertrophy
[142]
Vasculature Pulmonary vascular remodeling [143] Pulmonary vascular remodeling [144-146]
Basement membrane Thickened [76] Not thickened [76]
Extracellular matrix Subepithelial collagen deposition
(Myo)fibroblast accumulation
[101, 147] Airway wall fibrosis
Loss of alveolar walls
[76]Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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not sufficient to induce airway smooth muscle prolifera-
tion; muscarinic receptor agonists augment responses to
epidermal growth factor (EGF) and platelet-derived
growth factor (PDGF), in both human and bovine airway
smooth muscle [112,113]. This augmentation is consider-
able: the dose-response curve to PDGF is shifted both
upward and leftward, indicating that muscarinic receptors
increase the mitogenic response to any PDGF concentra-
tion. Moreover, muscarinic agonists can potentiate the
mitogenic response of myocytes in response to low con-
centrations of PDGF that would otherwise be insufficient
to stimulate cell growth. The inhibitory profile of a range
of subtype-selective antagonists (4-DAMP and DAU5884,
but not gallamine) demonstrates the exclusive involve-
ment of muscarinic M3 receptors in this effect [113] (Table
1). The importance of this potentiating effect is demon-
strated in vivo: repeated exposures of sensitized guinea
pigs to ovalbumin increases airway smooth muscle mass
in the small, non-cartilaginous airways, which is largely
inhibited by treatment with the anticholinergic agent tio-
tropium bromide [3]. In contrast, tiotropium bromide
itself had no effect on airway smooth muscle mass, either
in the cartilaginous or non-cartilaginous airways, which
corroborates the in vitro findings that muscarinic receptor
stimulation by itself is not sufficient to induce mitogenic
responses.
The mechanisms that underlie the pro-mitogenic effects
of muscarinic receptor stimulation have not yet been stud-
ied in detail. However, several intracellular signaling path-
ways have been identified that regulate the synergistic
mitogenic interaction of other GPCR agonists with growth
factors in airway smooth muscle (Figure 3). These path-
ways are not necessarily the same for every GPCR agonist;
however, those studies do offer some important clues. The
GPCR agonist thrombin augments EGF-induced prolifer-
ation through a pathway involving Gβγ, phosphatidyli-
nositol-3-kinase, Akt and p70S6kinase [114]. Although
thrombin is mitogenic by itself and therefore presumably
differs in its signaling profile from muscarinic receptor
agonists, this pathway is of interest as synergistic activa-
tion of p70S6kinase by carbachol and EGF has been noted
in human airway smooth muscle cells [112]. This
mitogenic synergism might also involve PKC; this enzyme
is responsible for the potentiating effects of the GPCR ago-
nist bradykinin with EGF in airway smooth muscle [115],
and regulates p70S6kinase activity [116,117]. PKC also
regulates p42/p44 MAP kinase activation by muscarinic
receptor agonists in airway smooth muscle [4]. The
involvement of the small G protein RhoA in synergism
induced by GPCR agonists and growth factors should also
be considered [118], which is interesting given that RhoA
expression is increased in animal models of asthma and
COPD, as discussed before. Clearly, further studies are
required to unravel in detail the signaling pathways
involved in the potentiating effects of muscarinic receptor
agonists on growth factor-induced airway smooth muscle
proliferation.
Mesenchymal cell differentiation
Mediators that drive contractile protein expression (e.g.
TGF-β) are thought to play an important role in the differ-
entiation of proliferating mesenchymal cells into mature
airway smooth muscle cells, in airway smooth muscle cell
hypertrophy, and in myofibroblast accumulation
[119,120]. These responses, together with smooth muscle
cell proliferation, contribute to increased airway smooth
muscle mass in asthma, and possibly in COPD
[101,119,121,122]. Increased expression of contractile
apparatus associated proteins likely plays an important
role in determining both airway bronchoconstrictor
responsiveness and the extent of airway remodeling in
asthma and COPD (Table 3) [110].
Mesenchymal cells from all individual airway wall com-
partments (adventitial fibroblasts, airway smooth muscle
cells, mucosal fibroblasts) can be induced to acquire a
more contractile phenotype, characterized by increases in
smooth muscle specific protein expression, such as
smooth muscle (sm)-α-actin, sm-myosin heavy chain
(MHC) and desmin [123-125]. Induction of contractile
protein gene transcription and protein translation in air-
way smooth muscle cells and fibroblasts is regulated by at
least two pathways: the RhoA/Rho-kinase pathway and
the phosphatidylinositol-3-kinase (PI3K)/mammalian
target of rapamycin (mTOR)/p70S6kinase pathway
[122,126] (Figure 3). There also appears to be a parallel
and significant role for PKC as a modulator of the contri-
bution of these pathways in the control of smooth muscle
specific gene transcription, and protein accumulation
[110,127]. Both the RhoA and PI3K pathways can be acti-
vated by muscarinic receptor agonists [43,112], and may
be involved in mediating effects of muscarinic receptor
agonists on SM22 and sm-MHC promoter activity [128].
Muscarinic receptor stimulation also leads to increased
levels of sm-α-actin and sm-MHC mRNA in intact bovine
tracheal smooth muscle strips, an effect that was also
linked to mechanical strain applied to the strips [129].
Inhibition of PKC leads to an increase in RhoA-dependent
transcription of SM22 and smMHC promoters [127].
Since PKC is strongly activated by muscarinic receptor
agonists, therefore the contribution of this signaling path-
way in the control of smooth muscle gene transcription
needs to be established more clearly. In addition, Ca2+
dependent pathways, induced by high concentrations of
muscarinic receptor agonists, modulate smooth muscle
specific contractile protein expression and contractility in
organ-cultured bovine tracheal smooth muscle strips
[130]. This indicates that the effects of muscarinic recep-
tors are under tight control of multiple pathways. FutureRespiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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studies are clearly warranted in this area to better under-
stand the interplay between the multiple pathways
induced by muscarinic receptors, and their significance as
determinants of airway smooth muscle differentiation
and cellular hypertrophy.
Repeated exposures of sensitized guinea pigs to ovalbu-
min cause a ~4-fold increase in pulmonary sm-MHC
expression with little effect on sm-α-actin expression [3].
Since sm-MHC is a far more stringent marker for mature
airway smooth muscle cells than sm-α-actin, which is a
more general marker for lung cells of mesenchymal origin
[125], these results indicate that maturation of differenti-
ated mesenchymal cells may have occurred in this model.
Indeed, the contractile response of tracheal smooth mus-
cle strips to methacholine was increased in the allergen
challenged animals, whereas muscle mass in the large air-
ways had not changed. Treatment of these animals with
tiotropium bromide significantly inhibited the ovalbu-
min-induced sm-MHC expression and increases in tra-
cheal contractility, indicating that endogenous
acetylcholine contributes to these effects [3]. Collectively,
Pathways involved in mesenchymal cell proliferation and differentiation induced by G protein coupled receptors (GPCRs) Figure 3
Pathways involved in mesenchymal cell proliferation and differentiation induced by G protein coupled receptors 
(GPCRs). G protein coupled muscarinic receptors activate signaling cascades resulting in p42/p44 MAP kinase (MAPK), Rho-
kinase and phosphatidyl-inositol-3-kinase (PI3K) activity. In addition, the signaling output of receptor tyrosine kinases (RTKs) is 
enhanced. Activation of the PI3K pathway appears to be particularly important in mesenchymal cell proliferation and differenti-
ation. With Akt and mammalian target of rapamycin (mTOR) as signaling intermediates, PI3K activates p70S6K, which is 
involved in ribosome mediated protein translation. p42/p44 MAPK, activated by the sequential activation of Ras, Raf and MEK, 
also activates p70S6K and plays an important role in the induction of transcription factors involved in cell cycle progression. 
Rho-kinase activated transcription factors also play a central role in smooth muscle specific gene transcription, ultimately medi-
ating the accumulation of contractile and contraction regulatory proteins. See the text for further detail.Respiratory Research 2006, 7:73 http://respiratory-research.com/content/7/1/73
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these studies point to an important role for acetylcholine
and muscarinic receptors in mesenchymal cell remode-
ling in allergic airways disease. The effects of muscarinic
receptor antagonists on airway wall remodeling in animal
models of COPD have not yet been investigated.
Other aspects of airway remodeling
Evidence of the involvement of muscarinic receptor stim-
ulation in other aspects of airway remodeling in asthma
and COPD is scarce, mainly because this has not yet
received sufficient attention to date. Since G-protein cou-
pled receptor signaling has been associated with extracel-
lular matrix production [131] and pulmonary vascular
smooth muscle cell proliferation [132], effects of mus-
carinic receptor agonists on extracellular matrix remode-
ling and pulmonary vascular remodeling could be
envisaged, though entirely speculative at this point. In
addition, a role for muscarinic receptors in goblet cell
hyperplasia and mucus gland hypertrophy has been pos-
tulated (see section on mucus hypersecretion). Future
studies are clearly required to investigate the effects of
muscarinic receptors on these aspects of airway remode-
ling.
Therapeutic implications
Collectively, the observations we have discussed in this
review suggest significant hitherto unexpected therapeutic
implications. Thus, anticholinergic therapy could achieve
far reaching and significant controller effects for chronic
asthma and COPD that extend its capacity as reliever med-
ications to promote bronchodilation. Based on the find-
ings and considerations presented above, it could be
envisaged that anticholinergics inhibit airway inflamma-
tion and limit airway remodeling, retarding the progres-
sive decline in lung function in asthma and COPD
patients.
Though previous studies using ipratropium bromide indi-
cate no improvement in the annual decline in lung func-
tion in patients with obstructive airways diseases [132],
these therapeutic outcomes may relate to limitations of
this drug. Ipratropium bromide is short-acting, whereas
the recently introduced anticholinergic agent tiotropium
bromide is long-acting and more potent. In addition, tio-
tropium bromide has a considerably longer relative half-
life of dissociation from muscarinic M3 and M1 receptors
than from muscarinic M2  receptors, making the drug
'kinetically selective' for M3 and M1 receptors [5,133,134].
It is still debatable as to whether this kinetic selectivity is
clinically important; however, since M2  autoreceptor
blockade is associated with enhanced acetylcholine out-
flow from the vagal nerve, whereas muscarinic M3 recep-
tor blockade inhibits most of the postjunctional effects of
acetylcholine (as described above) some beneficial effects
of this property could be envisaged.
Indeed, a recent study indicates that tiotropium bromide
induces a marked reduction in lung function decline of
COPD patients [6]. Although this study was retrospective,
the results of this study were remarkable: the mean
decline in FEV1 in one year was 58 ml in the placebo group
vs. 12 ml in the tiotropium group. This reduction has not
been observed with ipratropium bromide in COPD
patients [133]. Tiotropium bromide is also superior to
ipratropium bromide on other aspects, both with respect
to spirometry, health related quality of life and number of
exacerbations in COPD patients [134]. In view of our own
recent findings using a guinea pig model of ongoing aller-
gic asthma [3], showing that tiotropium bromide protects
against allergen-induced increases in airway smooth mus-
cle thickening, contractile protein accumulation and tra-
cheal hypercontractility, the drug tiotropium bromide
might also be effective in slowing or preventing airway
remodeling in chronic asthma. Future studies are required
to translate these findings to asthma patients, however.
Conclusion
Acetylcholine is a parasympathetic neurotransmitter and
an autocrine or paracrine hormone that regulates airway
smooth muscle contraction, mucus production, airway
inflammation and airway remodeling. The release of ace-
tylcholine, and the expression of several effector systems
central in muscarinic regulation of airway function are
enhanced in asthma and COPD, suggesting that the
effects of acetylcholine could contribute significantly to
the pathophysiology of these obstructive airways diseases.
Recent clinical and experimental findings support this
hypothesis, suggesting that anticholinergics, most notably
the long-acting tiotropium bromide, could achieve reduc-
tions in airway remodeling and lung function decline in
addition to its effects as a bronchodilator.
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